Emerging within the UK, retatrutide, a novel compound , is sparking considerable buzz within the scientific community regarding its ability for body control . This dual GIP and GLP-1 agent agonist seems to deliver a significant advantage over existing therapies, showing promising results in preliminary clinical trials . Researchers suggest its part